| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
2,3-Dinor-11Beta-Prostaglandin F2 Alpha, Urine
MessageTO BE SENT TO MAYO/ COLLECT M-W ONLY
Test Code
23BPG
CPT Codes
84150
Preferred Specimen
Preferred: 24-hour urine collection
Collection Instructions:
1. Collect urine for 24 hours.
2. Refrigerate specimen during collection, and send specimen refrigerated.
Collection Instructions:
1. Collect urine for 24 hours.
2. Refrigerate specimen during collection, and send specimen refrigerated.
Patient Preparation
Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to collecting a specimen.
Minimum Volume
Specimen Volume: 4 mL
Other Acceptable Specimens
RANDOM URINE
Specimen Stability
Refrigerated (preferred) 14 days
Frozen 30 days
Ambient 8 hours
Frozen 30 days
Ambient 8 hours
Clinical Significance
2,3-Dinor-11beta-prostaglandin F2 alpha is the most abundant metabolic product of prostaglandins released by activated mast cells. Systemic mastocytosis (SM) is a disease in which clonally derived mast cells accumulate in peripheral tissues. Degranulation of these mast cells releases large amounts of histamines, prostaglandins, leukotrienes, and tryptase.
The World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria: abnormal mast cell morphology, KIT Asp816Val mutation, CD25-positive mast cells, or serum tryptase greater than 20 ng/mL. Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies.
Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine (NMH), 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG), or leukotriene E4 (LTE4) are consistent with the diagnosis of systemic mast cell disease.
The World Health Organization diagnostic criteria for SM require the presence of elevated mast cell counts on a bone marrow biopsy and 1 of the following minor criteria: abnormal mast cell morphology, KIT Asp816Val mutation, CD25-positive mast cells, or serum tryptase greater than 20 ng/mL. Alternatively, SM diagnosis can be made with the presence of 3 minor criteria in the absence of abnormal bone marrow studies.
Measurement of mast cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of serum tryptase, urinary N-methylhistamine (NMH), 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG), or leukotriene E4 (LTE4) are consistent with the diagnosis of systemic mast cell disease.
Performing Laboratory
Mayo Clinic
200 First St. SW
Rochester, MN 55905
Phone: 507-284-2511